Type 2 immunity, illustrated by T helper 2 lymphocytes (Th2) and downstream cytokines (IL-4, IL-13, IL-31) as well as group 2 innate lymphoid cells (ILC2), is important in host defense and wound healing.1 The hallmark of type 2 inflammation is eosinophilia and/or high IgE counts and is best recognized in atopic diathesis. Persistent eosinophilia, such as seen in hypereosinophilic syndromes, leads to fibrosis and hence therapeutic Type 2 inhibition in fibrotic diseases is of high interest. Furthermore, as demonstrated in cutaneous T cell lymphoma, advanced disease is characterized by Th1 to Th2 switch allowing cancer progression and immunosuppression. Development of targeted monoclonal antibodies against IL-4Rα (eg, dupilumab) led to a paradigm shift for the treatment of atopic dermatitis (AD) and stimulated research to better understand the role of Type 2 inflammation in other skin conditions. In this review, we summarize up to date knowledge on the role of Type 2 inflammation in skin diseases other than AD and highlight whether the use of Type 2 targeted therapies has been documented or is being investigated in clinical trials. This manuscript reviews the role of Type 2 inflammation in dermatitis, neurodermatitis, IgE-mediated dermatoses (eg, bullous pemphigoid, chronic spontaneous urticaria), sclerodermoid conditions and skin neoplasms.
HarrisNL.LokeP. Recent advances in Type-2-cell-mediated immunity: insights from helminth infection. Immunity. 2017;47(6):1024-1036.doi:10.1016/j.immuni.2017.11.01529262347
2.
HiraharaK.NakayamaT. Cd4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm. Int Immunol. 2016;28(4):163-171.doi:10.1093/intimm/dxw00626874355
3.
AbbasAKL.AndrewH. Basic Immunology: Functions And Disorders Of The Immune System. 3 ed. Elsevier Saunders; 2011.
4.
LuckheeramRV.ZhouR.VermaAD.XiaB. CD4+ T cells: differentiation and functions. Clin Dev Immunol. 2012;2012(12):925135.doi:10.1155/2012/92513522474485
YosipovitchG.RosenJD.HashimotoT. Itch: from mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018;142(5):1375-1390.doi:10.1016/j.jaci.2018.09.00530409247
7.
RatnarajahK.LeM.MuntyanuA.MathieuS.NigenS.LitvinovIV. Inhibition of IL-13: a new pathway for atopic dermatitis. J Cutan Med Surg. 2020;1203475420982553.
Rafei-ShamsabadiDA.KloseCSN.HalimTYF.TanriverY.JakobT. Context dependent role of type 2 innate lymphoid cells in allergic skin inflammation. Front Immunol. 2019;10:2591.doi:10.3389/fimmu.2019.0259131781103
HuangY.PaulWE. Inflammatory group 2 innate lymphoid cells. Int Immunol. 2016;28(1):23-28.doi:10.1093/intimm/dxv04426232596
13.
WynnTA.RamalingamTR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18(7):1028-1040.doi:10.1038/nm.280722772564
14.
NguyenJK.AustinE.HuangA.MamalisA.JagdeoJ. The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets. Arch Dermatol Res. 2020;312(2):81-92.doi:10.1007/s00403-019-01972-331493000
15.
WynnTA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 2004;4(8):583-594.doi:10.1038/nri141215286725
ChenJK.JacobSE.NedorostSTet al. A pragmatic approach to patch testing atopic dermatitis patients: clinical recommendations based on expert consensus opinion. Dermatitis. 2016;27(4):186-192.doi:10.1097/DER.000000000000020827427820
18.
BourkeJ.CoulsonI.EnglishJ. British association of dermatologists therapy G, audit S. guidelines for the management of contact dermatitis: an update. Br J Dermatol. 2009;160(5):946-954.
19.
MowadCM.AndersonB.ScheinmanP.PootongkamS.NedorostS.BrodB. Allergic contact dermatitis: patient management and education. J Am Acad Dermatol. 2016;74(6):1043-1054.doi:10.1016/j.jaad.2015.02.114427185422
20.
JoshiSR.KhanDA. Effective use of Dupilumab in managing systemic allergic contact dermatitis. Dermatitis. 2018;29(5):282-284.doi:10.1097/DER.000000000000040930179979
21.
JacobSE.SungCT.MachlerBC. Dupilumab for systemic allergy syndrome with dermatitis. Dermatitis. 2019;30(2):164-167.doi:10.1097/DER.000000000000044630829809
22.
GoldminzAM.ScheinmanPL. A case series of dupilumab-treated allergic contact dermatitis patients. Dermatol Ther. 2018;31(6):e12701.doi:10.1111/dth.1270130246906
23.
ChipalkattiN.LeeN.ZancanaroP.DumontN.DonovanC.RosmarinD. Dupilumab as a treatment for allergic contact dermatitis. Dermatitis. 2018;29(6):347-348.doi:10.1097/DER.000000000000041430346326
24.
MachlerBC.SungCT.DarwinE.JacobSE. Dupilumab use in allergic contact dermatitis. J Am Acad Dermatol. 2019;80(1):280-281.doi:10.1016/j.jaad.2018.07.04330092326
25.
HendricksAJ.YosipovitchG.ShiVY. Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review. J Dermatolog Treat. 2021;32(1):19-28.doi:10.1080/09546634.2019.168922731693426
26.
ChipalkattiN.LeeN.ZancanaroP.DumontN.KachukC.RosmarinD. A retrospective review of dupilumab for atopic dermatitis patients with allergic contact dermatitis. J Am Acad Dermatol. 2019;80(4):1166-1167.doi:10.1016/j.jaad.2018.12.04830630024
27.
LeonardA.Guttman-YasskyE. The unique molecular signatures of contact dermatitis and implications for treatment. Clin Rev Allergy Immunol. 2019;56(1):1-8.doi:10.1007/s12016-018-8685-029754191
28.
DhingraN.ShemerA.Correa da RosaJet al. Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. J Allergy Clin Immunol. 2014;134(2):362-372.doi:10.1016/j.jaci.2014.03.00924768652
29.
TamauchiH.AmohY.ItohMet al. Gata-3 regulates contact hyperresponsiveness in a murine model of allergic dermatitis. Immunobiology. 2012;217(4):446-454.doi:10.1016/j.imbio.2011.10.00922112437
30.
KitagakiH.OnoN.HayakawaK.KitazawaT.WatanabeK.ShioharaT. Repeated elicitation of contact hypersensitivity induces a shift in cutaneous cytokine milieu from a T helper cell type 1 to a T helper cell type 2 profile. J Immunol. 1997;159(5):2484-2491.9278342
RaffiJ.SureshR.BottoN.MuraseJE. The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: a retrospective chart review. J Am Acad Dermatol. 2020;82(1):132-138.doi:10.1016/j.jaad.2019.09.02831562940
33.
StoutM.SilverbergJI. Variable impact of dupilumab on patch testing results and allergic contact dermatitis in adults with atopic dermatitis. J Am Acad Dermatol. 2019;81(1):157-162.doi:10.1016/j.jaad.2019.03.02030885752
34.
LyndeC.GuentherL.DiepgenTLet al. Canadian hand dermatitis management guidelines. J Cutan Med Surg. 2010;14(6):267-284.doi:10.2310/7750.2010.0909421084020
35.
FowlerJF.GhoshA.SungJet al. Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs. J Am Acad Dermatol. 2006;54(3):448-457.doi:10.1016/j.jaad.2005.11.105316488296
36.
VeienNK.HattelT.LaurbergG. Hand eczema: causes, course, and prognosis II. Contact Dermatitis. 2008;58(6):335-339.doi:10.1111/j.1600-0536.2008.01346.x18503682
37.
KingT.McKennaJ.AlexandroffAB. Alitretinoin for the treatment of severe chronic hand eczema. Patient Prefer Adherence. 2014;8:1629-1634.doi:10.2147/PPA.S3883025525339
38.
NandaS.NagraniN.MacQuhaeF.NicholsA. A case of complete resolution of severe plantar Dyshidrotic eczema with Dupilumab. J Drugs Dermatol. 2019;18(2):211-212.30811150
39.
OosterhavenJAF.RomeijnGLE.SchuttelaarMLA. Dupilumab treatment of very severe refractory atopic hand eczema. JAMA Dermatol. 2018;154(8):969-970.doi:10.1001/jamadermatol.2018.202729971331
40.
WestonGK.HooperJ.StroberBE. Dupilumab in the treatment of Dyshidrosis: a report of two cases. J Drugs Dermatol. 2018;17(3):355-356.29537454
HallingA-S.ZachariaeC.ThyssenJP. Severe treatment-resistant acute and recurrent vesicular chronic hand eczema successfully treated with dupilumab. Contact Dermatitis. 2020;83(1):37-38.doi:10.1111/cod.1350132087035
43.
LeeN.ChipalkattiN.ZancanaroP.KachukC.DumontN.RosmarinD. A retrospective review of Dupilumab for hand dermatitis. Dermatology. 2019;235(3):187-188.doi:10.1159/00049648130726838
44.
Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids: ClinicalTrials.gov; [updated Published: [Mar 4, 2019]. https://clinicaltrials.gov/ct2/show/NCT03861455
45.
PereiraMP.SteinkeS.ZeidlerCet al. European Academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018;32(7):1059-1065.doi:10.1111/jdv.14570
46.
HarrisB.HarrisK.PenneysNS. Demonstration by S-100 protein staining of increased numbers of nerves in the papillary dermis of patients with prurigo nodularis. J Am Acad Dermatol. 1992;26(1):56-58.doi:10.1016/0190-9622(92)70006-21732336
47.
FukushiS.YamasakiK.AibaS. Nuclear localization of activated STAT6 and STAT3 in epidermis of Prurigo nodularis. Br J Dermatol. 2011;165(5):990-996.doi:10.1111/j.1365-2133.2011.10498.x21711341
48.
WilliamsKA.HuangAH.BelzbergM.KwatraSG. Prurigo nodularis: pathogenesis and management. J Am Acad Dermatol. 2020;83(6):1567-1575.doi:10.1016/j.jaad.2020.04.18232461078
BeckKM.YangEJ.SekhonS.BhutaniT.LiaoW. Dupilumab treatment for generalized prurigo nodularis. JAMA Dermatol. 2019;155(1):118-120.doi:10.1001/jamadermatol.2018.391230427994
51.
MollanazarNK.ElgashM.WeaverL.Valdes-RodriguezR.HsuS. Reduced itch associated with Dupilumab treatment in 4 patients with prurigo nodularis. JAMA Dermatol. 2019;155(1):121-122.doi:10.1001/jamadermatol.2018.390630427989
52.
HolmJG.AgnerT.SandC.ThomsenSF. Dupilumab for prurigo nodularis: case series and review of the literature. Dermatol Ther. 2020;33(2):e13222.doi:10.1111/dth.1322231917498
53.
RambhiaPH.LevittJO. Recalcitrant prurigo nodularis treated successfully with dupilumab. JAAD Case Rep. 2019;5(5):471-473.doi:10.1016/j.jdcr.2019.03.01631192991
54.
FerrucciS.TavecchioS.BertiE.AngileriL. Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy. J Dermatolog Treat. 2019:1-2.
55.
CalugareanuA.JachietM.LepelletierCet al. Dramatic improvement of generalized prurigo nodularis with dupilumab. J Eur Acad Dermatol Venereol. 2019;33(8):e303-e304.doi:10.1111/jdv.1558430893496
56.
CriadoPR.PincelliTP.CriadoRFJ. Dupilumab as a useful treatment option for prurigo nodularis in an elderly patient with atopic diathesis. Int J Dermatol. 2020;59(10)doi:10.1111/ijd.14994
57.
GiuraMT.ViolaR.FierroMT.RiberoS.OrtoncelliM. Efficacy of dupilumab in prurigo nodularis in elderly patient. Dermatol Ther. 2020;33(1):e13201.doi:10.1111/dth.1320131856368
TanisR.FerencziK.PayetteM. Dupilumab treatment for prurigo nodularis and pruritis. J Drugs Dermatol. 2019;18(9):940-942.31524352
60.
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable: ClinicalTrials.gov; [updated [Dec 3, 2019][Jul 19, 2020].]. https://clinicaltrials.gov/ct2/show/NCT04183335
61.
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable: ClinicalTrials.gov; [updated [Dec 17, 2019][Jul 19, 2020]]. https://clinicaltrials.gov/ct2/show/NCT04202679
62.
CornelissenC.Lüscher-FirzlaffJ.BaronJM.LüscherB. Signaling by IL-31 and functional consequences. Eur J Cell Biol. 2012;91(6-7):552-566.doi:10.1016/j.ejcb.2011.07.00621982586
63.
SonkolyE.MullerA.LauermaAIet al. Il-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411-417.doi:10.1016/j.jaci.2005.10.03316461142
64.
GibbsBF.PatsinakidisN.RaapU. Role of the pruritic cytokine IL-31 in autoimmune skin diseases. Front Immunol. 2019;10:1383.doi:10.3389/fimmu.2019.0138331281316
65.
SteinhoffM.BienenstockJ.SchmelzM.MaurerM.WeiE.BíróT. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol. 2006;126(8):1705-1718.doi:10.1038/sj.jid.570023116845410
66.
TanakaA.AritaK.Lai-CheongJE.PalissonF.HideM.McGrathJA. New insight into mechanisms of pruritus from molecular studies on familial primary localized cutaneous amyloidosis. Br J Dermatol. 2009;161(6):1217-1224.doi:10.1111/j.1365-2133.2009.09311.x19663869
67.
StänderS.YosipovitchG.LegatFJet al. Trial of Nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med. 2020;382(8):706-716.doi:10.1056/NEJMoa190831632074418
68.
BartolucciS.NetchiporoukE.LitvinovIV. Recent therapeutic advances in pruritus management for atopic dermatitis patients: a welcome addition of Asivatrep to our arsenal of future topical treatments. J Cutan Med Surg. 2019;23(5):551-552.doi:10.1177/120347541986050131478771
69.
FowlerE.YosipovitchG. A new generation of treatments for itch. Acta Derm Venereol. 2020;100(2):37-45.doi:10.2340/00015555-334731940047
FangD.EllyC.GaoBet al. Dysregulation of T lymphocyte function in Itchy mice: a role for itch in Th2 differentiation. Nat Immunol. 2002;3(3):281-287.doi:10.1038/ni76311828324
74.
FeldM.GarciaR.BuddenkotteJet al. The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves. J Allergy Clin Immunol. 2016;138(2):e24:500-508.doi:10.1016/j.jaci.2016.02.02027212086
75.
YangEJ.MuraseJE. Recalcitrant anal and genital pruritus treated with dupilumab. Int J Womens Dermatol. 2018;4(4):223-226.doi:10.1016/j.ijwd.2018.08.01030627621
76.
KremerN.SnastI.CohenESet al. Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature. Am J Clin Dermatol. 2019;20(2):209-216.doi:10.1007/s40257-018-0401-630421306
77.
Giménez-ArnauAM. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety. Expert Opin Biol Ther. 2017;17(3):375-385.doi:10.1080/14712598.2017.128590328125304
78.
GomesN.MirandaJ.LopesSet al. Omalizumab in the treatment of hyper-IgE syndrome: 2 case reports. J Investig Allergol Clin Immunol. 2020;30(3):191-192.doi:10.18176/jiaci.046931820738
79.
WieserJK.KuehnGJ.PrezzanoJCet al. Improvement in a patient with hypereosinophilic syndrome after initiation of dupilumab treatment. JAAD Case Rep. 2020;6(4):292-295.doi:10.1016/j.jdcr.2020.02.03032258301
80.
FelicianiC.TotoP.Mohammad PourS.CoscioneG.AmerioP.AmerioP.PourSM.AmerioP. A TH2-like cytokine response is involved in bullous pemphigoid. The role of IL-4 and IL-5 in the pathogenesis of the disease. Int J Immunopathol Pharmacol. 1999;12(2):55-61.doi:10.1177/20587392990120020212783647
81.
GiomiB.CaproniM.CalzolariA.BianchiB.FabbriP. Th1, Th2 and TH3 cytokines in the pathogenesis of bullous pemphigoid. J Dermatol Sci. 2002;30(2):116-128.doi:10.1016/S0923-1811(02)00067-112413767
82.
Gounni AbdelilahS.WellemansV.AgouliMet al. Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines. Clin Immunol. 2006;120(2):220-231.doi:10.1016/j.clim.2006.03.01416782408
83.
Ben-ShoshanD.LitvinovIV.NetchiporoukE. The future of bullous pemphigoid (BP): new and promising drugs may revolutionize treatment course for bp patients. J Cutan Med Surg. 2020;24(2):191-192.doi:10.1177/120347541988886732208024
84.
GenoveseG.Di ZenzoG.CozzaniE.BertiE.CugnoM.MarzanoAV. New insights into the pathogenesis of bullous pemphigoid: 2019 update. Front Immunol. 2019;10:1506.doi:10.3389/fimmu.2019.0150631312206
MessinghamKN.CroweTP.FairleyJA. The intersection of IgE autoantibodies and eosinophilia in the pathogenesis of bullous pemphigoid. Front Immunol. 2019;10:2331.doi:10.3389/fimmu.2019.0233131636640
87.
NagelA.LangA.EngelDet al. Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. Clin Immunol. 2010;134(3):320-330.doi:10.1016/j.clim.2009.11.00620015693
88.
FreirePC.MuñozCH.StinglG. Ige autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants. Br J Dermatol. 2017;177(6):1644-1653.doi:10.1111/bjd.1592428868796
89.
van BeekN.SchulzeFS.ZillikensD.SchmidtE. Ige-Mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases. Expert Rev Clin Immunol. 2016;12(3):267-277.doi:10.1586/1744666X.2016.112309226588556
90.
HashimotoT.OhzonoA.TeyeKet al. Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid. Br J Dermatol. 2017;177(1):141-151.doi:10.1111/bjd.1511427716903
91.
MoriuchiR.NishieW.UjiieH.NatsugaK.ShimizuH. In vivo analysis of IgE autoantibodies in bullous pemphigoid: a study of 100 cases. J Dermatol Sci. 2015;78(1):21-25.doi:10.1016/j.jdermsci.2015.01.01325724363
92.
KowalskiEH.KneibnerD.KridinK.AmberKT. Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. Autoimmun Rev. 2019;18(5):526-534.doi:10.1016/j.autrev.2019.03.00930844553
93.
GüntherC.Carballido-PerrigN.KoppT.CarballidoJM.PfeifferC. Ccl18 is expressed in patients with bullous pemphigoid and parallels disease course. Br J Dermatol. 2009;160(4):747-755.doi:10.1111/j.1365-2133.2008.08979.x19120345
94.
AbdatR.WaldmanRA.de BedoutVet al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol. 2020;83(1):46-52.doi:10.1016/j.jaad.2020.01.08932179082
95.
Ben-ShoshanM.GrattanCE. Management of pediatric urticaria with review of the literature on chronic spontaneous urticaria in children. J Allergy Clin Immunol Pract. 2018;6(4):1152-1161.doi:10.1016/j.jaip.2018.02.01529550102
96.
KayeA.GordonSC.DeverapalliSC.HerMJ.RosmarinD. Dupilumab for the treatment of recalcitrant bullous pemphigoid. JAMA Dermatol. 2018;154(10):1225-1226.doi:10.1001/jamadermatol.2018.252630140849
97.
SeidmanJS.EichenfieldDZ.OrmeCM. Dupilumab for bullous pemphigoid with intractable pruritus. Dermatol Online J. 2019;25(11):13030/qt25q9w6r9.32045153
98.
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid: ClinicalTrials.gov; [updated [Dec 20, 2019][Jul 19, 2020]]. https://clinicaltrials.gov/ct2/show/NCT04206553
99.
IzumiK.BieberK.LudwigRJ. Current clinical trials in pemphigus and pemphigoid. Front Immunol. 2019;10:978.doi:10.3389/fimmu.2019.0097831130959
100.
FudgeJG.CrawfordRI. Bullous pemphigoid: a 10-year study of discordant results on direct immunofluorescence. J Cutan Med Surg. 2018;22(5):472-475.doi:10.1177/120347541877335929681159
101.
Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid: ClinicalTrials.gov; [updated [Aug 27, 2014][Jul 19, 2020]]. https://clinicaltrials.gov/ct2/show/results/NCT02226146
102.
NetchiporoukE.SassevilleD.MoreauL.HabelY.RahmeE.Ben-ShoshanM. Evaluating comorbidities, natural history, and predictors of early resolution in a cohort of children with chronic urticaria. JAMA Dermatol. 2017;153(12):1236-1242.doi:10.1001/jamadermatol.2017.318228973060
HideM.FrancisDM.GrattanCE.HakimiJ.KochanJP.GreavesMW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993;328(22):1599-1604.doi:10.1056/NEJM1993060332822047683772
105.
ChangJ.CattelanL.Ben-ShoshanM.LeM.NetchiporoukE. Management of pediatric chronic spontaneous urticaria: a review of current evidence and guidelines. J Asthma Allergy. 2021;14:187-199.doi:10.2147/JAA.S24976533727832
106.
BrunettiL.FrancavillaR.MinielloVLet al. High prevalence of autoimmune urticaria in children with chronic urticaria. J Allergy Clin Immunol. 2004;114(4):922-927.doi:10.1016/j.jaci.2004.07.04215480336
107.
NetchiporoukE.MoreauL.RahmeE.MaurerM.LejtenyiD.Ben-ShoshanM. Positive CD63 basophil activation tests are common in children with chronic spontaneous urticaria and linked to high disease activity. Int Arch Allergy Immunol. 2016;171(2):81-88.doi:10.1159/00045108427846634
108.
MuntyanuA.OucheneL.Ben-ShoshanM.NetchiporoukE. Ligelizumab is superior to omalizumab for chronic spontaneous urticaria. J Cutan Med Surg. 2020;24(2):201-202.doi:10.1177/120347541988887332208012
109.
NetchiporoukE.NguyenCH.ThuraisinghamT.JafarianF.MaurerM.Ben-ShoshanM. Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series. Pediatr Allergy Immunol. 2015;26(6):585-588.doi:10.1111/pai.1240726012951
110.
Alizadeh AghdamM.PieterseRH.KentiePA.RijkenF.KnulstAC.RöckmannH. Effective omalizumab interval prolongation in the treatment of chronic urticaria. J Allergy Clin Immunol Pract. 2020;8(10):3667-3668.doi:10.1016/j.jaip.2020.06.05632679351
111.
LeeJK.SimpsonRS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2019;7(5):1659-1661.doi:10.1016/j.jaip.2018.11.01830496828
Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab: ClinicalTrials.gov; [updated [Nov 27, 2019][Jul 12, 2020]]. https://clinicaltrials.gov/ct2/show/NCT04180488
KolkhirP.AltrichterS.MunozM.HawroT.MaurerM. New treatments for chronic urticaria. Ann Allergy Asthma Immunol. 2020;124(1):2-12.doi:10.1016/j.anai.2019.08.01431446134
119.
KalliF.CioniM.ParodiAet al. Increased frequency of interleukin-4 and reduced frequency of interferon-γ and IL-17-producing CD4+ and CD8+ cells in scleromyxedema. J Eur Acad Dermatol Venereol. 2020;34(5):1092-1097.doi:10.1111/jdv.1613631912592
120.
TredgetEE.YangL.DelehantyM.ShankowskyH.ScottPG. Polarized Th2 cytokine production in patients with hypertrophic scar following thermal injury. J Interferon Cytokine Res. 2006;26(3):179-189.doi:10.1089/jir.2006.26.17916542140
121.
Shapouri-MoghaddamA.MohammadianS.VaziniHet al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233(9):6425-6440.doi:10.1002/jcp.2642929319160
122.
CutoloM.TrombettaAC.SoldanoS. Monocyte and macrophage phenotypes: a look beyond systemic sclerosis. Response to: ‘M1/M2 polarisation state of M-CSF blood-derived macrophages in systemic sclerosis’ by Lescoat et al. Ann Rheum Dis. 2019;78(11):e128.doi:10.1136/annrheumdis-2018-21437130269052
123.
LaurentP.JolivelV.ManickiPet al. Immune-mediated repair: a matter of plasticity. Front Immunol. 2017;8:454.doi:10.3389/fimmu.2017.0045428484454
124.
ZhuZ.DingJ.MaZ.IwashinaT.TredgetEE. Systemic depletion of macrophages in the subacute phase of wound healing reduces hypertrophic scar formation. Wound Repair Regen. 2016;24(4):644-656.doi:10.1111/wrr.1244227169512
125.
GieseckRL.WilsonMS.WynnTA. Type 2 immunity in tissue repair and fibrosis. Nat Rev Immunol. 2018;18(1):62-76.doi:10.1038/nri.2017.9028853443
Salmon-EhrV.RamontL.GodeauGet al. Implication of interleukin-4 in wound healing. Lab Invest. 2000;80(8):1337-1343.doi:10.1038/labinvest.378014110950124
128.
KaviratneM.HesseM.LeusinkMet al. Il-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol. 2004;173(6):4020-4029.doi:10.4049/jimmunol.173.6.402015356151
129.
BhogalRK.StoicaCM.McGahaTL.BonaCA. Molecular aspects of regulation of collagen gene expression in fibrosis. J Clin Immunol. 2005;25(6):592-603.doi:10.1007/s10875-005-7827-316380822
130.
GilleryP.FertinC.NicolasJFet al. Interleukin-4 stimulates collagen gene expression in human fibroblast monolayer cultures. Potential role in fibrosis. FEBS Lett. 1992;302(3):231-234.doi:10.1016/0014-5793(92)80448-P1601130
131.
PostlethwaiteAE.HolnessMA.KataiH.RaghowR. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest. 1992;90(4):1479-1485.doi:10.1172/JCI1160151401080
LeaskA.AbrahamDJ. Tgf-Beta signaling and the fibrotic response. Faseb J. 2004;18(7):816-827.doi:10.1096/fj.03-1273rev15117886
134.
MengX-M.Nikolic-PatersonDJ.LanHY. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12(6):325-338.doi:10.1038/nrneph.2016.4827108839
135.
OucheneL.MuntyanuA.LavouéJ.BaronM.LitvinovIV.NetchiporoukE. Toward understanding of environmental risk factors in systemic sclerosis [Formula: see text]. J Cutan Med Surg. 2021;25(2):188-204.doi:10.1177/120347542095795032988228
136.
YangX.YangJ.XingX.WanL.LiM. Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction. Arthritis Res Ther. 2014;16(1):R4.doi:10.1186/ar443024398084
137.
LiuX.GaoN.LiMet al. Elevated levels of CD4(+)CD25(+)FoxP3(+) T cells in systemic sclerosis patients contribute to the secretion of IL-17 and immunosuppression dysfunction. PLoS One. 2013;8(6):e64531.doi:10.1371/journal.pone.006453123776439
138.
BrembillaNC.MontanariE.TruchetetM-E.RaschiE.MeroniP.ChizzoliniC. Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. Arthritis Res Ther. 2013;15(5):R151.doi:10.1186/ar433424289089
139.
MeloniF.SolariN.CavagnaL.MorosiniM.MontecuccoCM.FiettaAM. Frequency of Th1, Th2 and Th17 producing T lymphocytes in bronchoalveolar lavage of patients with systemic sclerosis. Clin Exp Rheumatol. 2009;27(5):765-772.19917158
140.
HuangX-L.WangY-J.YanJ-Wet al. Role of anti-inflammatory cytokines IL-4 and IL-13 in systemic sclerosis. Inflamm Res. 2015;64(3-4):151-159.doi:10.1007/s00011-015-0806-025725697
141.
McGahaT.SaitoS.PhelpsRGet al. Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes. J Invest Dermatol. 2001;116(1):136-143.doi:10.1046/j.1523-1747.2001.00217.x11168809
142.
OngCJ.IpS.TehSJet al. A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice. Cell Immunol. 1999;196(1):60-68.doi:10.1006/cimm.1999.153710486156
SfikakisPP. Is IL-4 a potential therapeutic target in systemic sclerosis-associated pulmonary fibrosis?Clin Immunol. 2011;141(3):240-241.doi:10.1016/j.clim.2011.09.01021996458
145.
HasegawaM.FujimotoM.KikuchiK.TakeharaK. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol. 1997;24(2):328-332.9034992
146.
AllanoreY.WungP.SoubraneC.EsperetC.MarracheF.BejuitR. A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020.
147.
HassanM.WattersKA.NetchiporoukE. Linear discoid lupus erythematosus mimicking en coup de sabre morphea: A case report. SAGE Open Med Case Rep. 2019;7:2050313X19882843doi:10.1177/2050313X1988284331666954
148.
KurzinskiK.TorokKS. Cytokine profiles in localized scleroderma and relationship to clinical features. Cytokine. 2011;55(2):157-164.doi:10.1016/j.cyto.2011.04.00121536453
149.
Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma: ClinicalTrials.gov: [updated [Dec 16, 2019][Jul 19, 2020]]. https://clinicaltrials.gov/ct2/show/NCT04200755
150.
ShulmanLE. Diffuse fasciitis with eosinophilia: a new syndrome?Trans Assoc Am Physicians. 1975;88:70-86.1224441
151.
MertensJS.SeygerMMB.ThurlingsRM.RadstakeTRDJ.de JongEMGJ. Morphea and eosinophilic fasciitis: an update. Am J Clin Dermatol. 2017;18(4):491-512.doi:10.1007/s40257-017-0269-x28303481
152.
IhnH. Eosinophilic fasciitis: from pathophysiology to treatment. Allergol Int. 2019;68(4):437-439.doi:10.1016/j.alit.2019.03.00130910631
153.
ViallardJF.TaupinJL.RanchinV.LengB.PellegrinJL.MoreauJF. Analysis of leukemia inhibitory factor, type 1 and type 2 cytokine production in patients with eosinophilic fasciitis. J Rheumatol. 2001;28(1):75-80.11196547
154.
ZeiserR.BlazarBR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377(26):2565-2579.doi:10.1056/NEJMra170347229281578
155.
KrengerW.SnyderKM.ByonJC.FalzaranoG.FerraraJL. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol. 1995;155(2):585-593.7608537
156.
ShahNR.LeoneA.RothbaumR.DelostGRR.CooperK. Cutaneous chronic graft versus host disease in a symmetric distribution. Cureus. 2019;11(5)doi:10.7759/cureus.4614
157.
MartiresKJ.BairdK.SteinbergSMet al. Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. Blood. 2011;118(15):4250-4257.doi:10.1182/blood-2011-04-35024921791415
158.
NikolicB.LeeS.BronsonRT.GrusbyMJ.SykesM. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest. 2000;105(9):1289-1298.doi:10.1172/JCI789410792004
159.
YiT.ChenY.WangLet al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood. 2009;114(14):3101-3112.doi:10.1182/blood-2009-05-21940219602708
160.
BurmanAC.BanovicT.KunsRDet al. Ifngamma differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood. 2007;110(3):1064-1072.doi:10.1182/blood-2006-12-06398217449800
161.
JacobsohnDA.SchechterT.SeshadriR.ThormannK.DuerstR.KletzelM. Eosinophilia correlates with the presence or development of chronic graft-versus-host disease in children. Transplantation. 2004;77(7):1096-1100.doi:10.1097/01.TP.0000118409.92769.FA15087778
162.
DaneshpouyM.SocieG.LemannM.RivetJ.GluckmanE.JaninA. Activated eosinophils in upper gastrointestinal tract of patients with graft-versus-host disease. Blood. 2002;99(8):3033-3040.doi:10.1182/blood.V99.8.303311929797
163.
SkertC.DamianiD.MicheluttiAet al. Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. Bone Marrow Transplant. 2009;44(11):729-737.doi:10.1038/bmt.2009.8019398965
164.
ZhouL.AskewD.WuC.GilliamAC. Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol. 2007;127(2):281-292.doi:10.1038/sj.jid.570051716917493
DiazA.TanK.HeHet al. Keloid lesions show increased IL-4/IL-13 signaling and respond to Th2-targeting dupilumab therapy. J Eur Acad Dermatol Venereol. 2020;34(4):e161-e4.doi:10.1111/jdv.1609731747457
167.
GhazawiFM.NetchiporoukE.RahmeEet al. Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy. Cancer. 2017;123(18):3550-3567.doi:10.1002/cncr.3075828493286
168.
GhazawiFM.AlghazawiN.LeMet al. Environmental and other extrinsic risk factors contributing to the pathogenesis of cutaneous T cell lymphoma (CTCL). Front Oncol. 2019;9:300.doi:10.3389/fonc.2019.0030031106143
169.
Willerslev-OlsenA.BuusTB.NastasiCet al. Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome. Blood Cancer J. 2020;10(5):57.doi:10.1038/s41408-020-0324-332409671
170.
LeM.GhazawiFM.NetchiporoukE.LitvinovIV. The novel role of antibiotic treatment in the management of cutaneous T-cell lymphoma (CTCL) patients. J Cutan Med Surg. 2020;24(4):410-411.doi:10.1177/120347542092698132394726
171.
ChungCG.PoligoneB. Cutaneous T cell lymphoma: an update on pathogenesis and systemic therapy. Curr Hematol Malig Rep. 2015;10(4):468-476.doi:10.1007/s11899-015-0293-y26626770
172.
NetchiporoukE.LitvinovIV.MoreauL.GilbertM.SassevilleD.DuvicM. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. Cell Cycle. 2014;13(21):3331-3335.doi:10.4161/15384101.2014.96506125485578
173.
FujiiK. New therapies and immunological findings in cutaneous T-cell lymphoma. Front Oncol. 2018;8:198.doi:10.3389/fonc.2018.0019829915722
174.
MöbsM.GryzikS.HaidarA.HummeD.BeyerM.VanderseeS. Analysis of the IL-31 pathway in mycosis fungoides and Sézary syndrome. Arch Dermatol Res. 2015;307(6):479-485.doi:10.1007/s00403-014-1527-x25488078
175.
OlszewskaB.Sokołowska-WojdyłoM.LakomyJ.NowickiRJ. The ambiguous pruritogenic role of interleukin-31 in cutaneous T-cell lymphomas in comparison to atopic dermatitis: a review. Postepy Dermatol Alergol. 2020;37(3):319-325.doi:10.5114/ada.2020.9626032792870
176.
SingerEM.ShinDB.NattkemperLAet al. Il-31 is produced by the malignant T-cell population in cutaneous T-cell lymphoma and correlates with CTCL pruritus. J Invest Dermatol. 2013;133(12):2783-2785.doi:10.1038/jid.2013.22723698099
177.
DummerR.KohlO.GillessenJ.KägiM.BurgG. Peripheral blood mononuclear cells in patients with nonleukemic cutaneous T-cell lymphoma. reduced proliferation and preferential secretion of a T helper-2-like cytokine pattern on stimulation. Arch Dermatol. 1993;129(4):433-436.8466213
178.
VowelsBR.CassinM.VonderheidEC.RookAH. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol. 1992;99(1):90-94.doi:10.1111/1523-1747.ep126118771607682
179.
AsadullahK.HaeusslerA.SterryW.DöckeWD.VolkHD. Interferon gamma and tumor necrosis factor alpha mRNA expression in mycosis fungoides progression. Blood. 1996;88(2):757-758.doi:10.1182/blood.V88.2.757.bloodjournal8827578695829
180.
GantchevJ.Martínez VillarrealA.GunnS.ZetkaM.ØdumN.LitvinovIV. The ectopic expression of meiCT genes promotes meiomitosis and may facilitate carcinogenesis. Cell Cycle. 2020;19(8):837-854.doi:10.1080/15384101.2020.174390232223693
181.
LitvinovIV.CordeiroB.FredholmSet al. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines. Cell Cycle. 2014;13(18):2975-2982.doi:10.4161/15384101.2014.94775925486484
182.
LazaridouI.Ram-WolffC.BouazizJ-Det al. Dupilumab treatment in two patients with cutaneous T-cell lymphomas. Acta Derm Venereol. 2020;100(16):adv00271.doi:10.2340/00015555-357632556342
183.
MiyashiroD.VivarelliAG.GonçalvesF.Cury-MartinsJ.SanchesJA. Progression of mycosis fungoides after treatment with dupilumab: a case report. Dermatol Ther. 2020;33(6):e13880.doi:10.1111/dth.1388032558148
184.
HollinsLC.WirthP.FulchieroGJ, Jr.FoulkeGT. Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma. Cutis. 2020;106(2):E8-E11.doi:10.12788/cutis.007432941565
185.
EspinosaML.NguyenMT.AguirreASet al. Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients. J Am Acad Dermatol. 2020;83(1):197-199.doi:10.1016/j.jaad.2020.03.05032229275
186.
SteckO.BertschiNL.LutherFet al. Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sézary syndrome. J Eur Acad Dermatol Venereol. 2021;35(6):1337.doi:10.1111/jdv.1700133068311
187.
ValentP.KlionAD.HornyH-Pet al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130(3):607-612.doi:10.1016/j.jaci.2012.02.01922460074
188.
LeifermanKM.GleichGJ.PetersMS. Dermatologic manifestations of the hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27(3):415-441.doi:10.1016/j.iac.2007.07.00917868857
189.
SimonHU.PlötzSG.DummerR.BlaserK. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999;341(15):1112-1120.doi:10.1056/NEJM19991007341150310511609
190.
ShomaliW.GotlibJ. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. Am J Hematol. 2019;94(10):1149-1167.doi:10.1002/ajh.2561731423623
191.
SchrezenmeierH.ThoméSD.TewaldF.FleischerB.RaghavacharA. Interleukin-5 is the predominant eosinophilopoietin produced by cloned T lymphocytes in hypereosinophilic syndrome. Exp Hematol. 1993;21(2):358-365.8425573
192.
BankI.AmariglioN.ReshefAet al. The hypereosinophilic syndrome associated with CD4+CD3- helper type 2 (Th2) lymphocytes. Leuk Lymphoma. 2001;42(1-2):123-133.doi:10.3109/1042819010909768411699199
193.
RoufosseF.SchandenéL.SibilleCet al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol. 2000;109(3):540-548.doi:10.1046/j.1365-2141.2000.02097.x10886202
194.
OgboguPU.BochnerBS.ButterfieldJHet al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124(6):1319-1325.doi:10.1016/j.jaci.2009.09.02219910029
195.
OgboguPU.RosingDR.HorneMK. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27(3):457-475.doi:10.1016/j.iac.2007.07.00117868859
196.
ButtNM.LambertJ.AliSet al. Guideline for the investigation and management of eosinophilia. Br J Haematol. 2017;176(4):553-572.doi:10.1111/bjh.1448828112388
197.
PlötzS-G.SimonH-U.DarsowUet al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med. 2003;349(24):2334-2339.doi:10.1056/NEJMoa03126114668459
198.
KuangFL.FayMP.WareJet al. Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome. J Allergy Clin Immunol Pract. 2018;6(5):1518-1527.doi:10.1016/j.jaip.2018.04.03329751154
199.
KlionAD.LawMA.NoelP.KimY-J.HavertyTP.NutmanTB. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood. 2004;103(8):2939-2941.doi:10.1182/blood-2003-10-362015070668
200.
KuangFL.LegrandF.MakiyaMet al. Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome. N Engl J Med. 2019;380(14):1336-1346.doi:10.1056/NEJMoa181218530943337
201.
WroneDA.SwetterSM.EgbertBM.SmollerBR.KhavariPA. Increased proportion of aggressive-growth basal cell carcinoma in the Veterans Affairs population of Palo Alto, California. J Am Acad Dermatol. 1996;35(6):907-910.doi:10.1016/S0190-9622(96)90114-08959949
202.
LefrançoisP.XieP.GunnSet al. In silico analyses of the tumor microenvironment highlight tumoral inflammation, a Th2 cytokine shift and a mesenchymal stem cell-like phenotype in advanced in basal cell carcinomas. J Cell Commun Signal. 2020;14(2):245-254.doi:10.1007/s12079-020-00563-632198729
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
